213 related articles for article (PubMed ID: 32060421)
1. PTGES/PGE
Wang T; Jing B; Xu D; Liao Y; Song H; Sun B; Guo W; Xu J; Li K; Hu M; Liu S; Ling J; Kuang Y; Zhang T; Zhang S; Yao F; Zhou BP; Deng J
Oncogene; 2020 Apr; 39(15):3179-3194. PubMed ID: 32060421
[TBL] [Abstract][Full Text] [Related]
2. IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung.
Jing B; Wang T; Sun B; Xu J; Xu D; Liao Y; Song H; Guo W; Li K; Hu M; Zhang S; Ling J; Kuang Y; Zhang T; Zhou BP; Yao F; Deng J
Cancer Res; 2020 Feb; 80(4):784-797. PubMed ID: 31848193
[TBL] [Abstract][Full Text] [Related]
3. GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development.
Song H; Sun B; Liao Y; Xu D; Guo W; Wang T; Jing B; Hu M; Li K; Yao F; Deng J
Int J Cancer; 2019 Feb; 144(4):777-787. PubMed ID: 29992578
[TBL] [Abstract][Full Text] [Related]
4. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Kim SH; Roszik J; Cho SN; Ogata D; Milton DR; Peng W; Menter DG; Ekmekcioglu S; Grimm EA
Clin Cancer Res; 2019 Mar; 25(5):1650-1663. PubMed ID: 30538110
[TBL] [Abstract][Full Text] [Related]
5. Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling.
Zhong S; Yin H; Liao Y; Yao F; Li Q; Zhang J; Jiao H; Zhao Y; Xu D; Liu S; Song H; Gao Y; Liu J; Ma L; Pang Z; Yang R; Ding C; Sun B; Lin X; Ye X; Guo W; Han B; Zhou BP; Chin YE; Deng J
Cancer Res; 2015 May; 75(9):1801-14. PubMed ID: 25744720
[TBL] [Abstract][Full Text] [Related]
6. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis.
Deng J; Fujimoto J; Ye XF; Men TY; Van Pelt CS; Chen YL; Lin XF; Kadara H; Tao Q; Lotan D; Lotan R
Cancer Prev Res (Phila); 2010 Apr; 3(4):424-37. PubMed ID: 20354164
[TBL] [Abstract][Full Text] [Related]
7. Identification of Sca-1
Yin H; Jiang Z; Feng X; Ji Z; Jin W
Oncogene; 2020 Apr; 39(18):3754-3773. PubMed ID: 32157214
[TBL] [Abstract][Full Text] [Related]
8. Identification of Active Bronchioalveolar Stem Cells as the Cell of Origin in Lung Adenocarcinoma.
Yin H; Jing B; Xu D; Guo W; Sun B; Zhang J; Liao Y; Song H; Wang T; Liu S; Kuang Y; Hu M; Li K; Zhang S; Zhang H; Xu J; Li X; Du J; Wu Y; Wu Y; Wang Q; Yao F; Chin YE; Zhou BP; Deng J
Cancer Res; 2022 Mar; 82(6):1025-1037. PubMed ID: 35045987
[TBL] [Abstract][Full Text] [Related]
9. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.
Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB
Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128
[TBL] [Abstract][Full Text] [Related]
10. Gprc5a-knockout mouse lung epithelial cells predicts ceruloplasmin, lipocalin 2 and periostin as potential biomarkers at early stages of lung tumorigenesis.
Sun B; Guo W; Hu S; Yao F; Yu K; Xing J; Wang R; Song H; Liao Y; Wang T; Jiang P; Han B; Deng J
Oncotarget; 2017 Feb; 8(8):13532-13544. PubMed ID: 28088789
[TBL] [Abstract][Full Text] [Related]
11. A RIPK3-PGE
Yan G; Zhao H; Zhang Q; Zhou Y; Wu L; Lei J; Wang X; Zhang J; Zhang X; Zheng L; Du G; Xiao W; Tang B; Miao H; Li Y
Cancer Res; 2018 Oct; 78(19):5586-5599. PubMed ID: 30012671
[TBL] [Abstract][Full Text] [Related]
12. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.
Tao Q; Fujimoto J; Men T; Ye X; Deng J; Lacroix L; Clifford JL; Mao L; Van Pelt CS; Lee JJ; Lotan D; Lotan R
J Natl Cancer Inst; 2007 Nov; 99(22):1668-82. PubMed ID: 18000218
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation.
Barta P; Van Pelt C; Men T; Dickey BF; Lotan R; Moghaddam SJ
Mol Cancer; 2012 Jan; 11():4. PubMed ID: 22239913
[TBL] [Abstract][Full Text] [Related]
14. Gprc5a-deficiency confers susceptibility to endotoxin-induced acute lung injury via NF-κB pathway.
Liao Y; Song H; Xu D; Jiao H; Yao F; Liu J; Wu Y; Zhong S; Yin H; Liu S; Wang X; Guo W; Sun B; Han B; Chin YE; Deng J
Cell Cycle; 2015; 14(9):1403-12. PubMed ID: 25714996
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
16. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor.
Chen Y; Deng J; Fujimoto J; Kadara H; Men T; Lotan D; Lotan R
Cancer Res; 2010 Nov; 70(21):8917-26. PubMed ID: 20959490
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
18. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.
Fujimoto J; Kadara H; Garcia MM; Kabbout M; Behrens C; Liu DD; Lee JJ; Solis LM; Kim ES; Kalhor N; Moran C; Sharafkhaneh A; Lotan R; Wistuba II
J Thorac Oncol; 2012 Dec; 7(12):1747-1754. PubMed ID: 23154545
[TBL] [Abstract][Full Text] [Related]
19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
20. Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.
Yang F; Wei Y; Cai Z; Yu L; Jiang L; Zhang C; Yan H; Wang Q; Cao X; Liang T; Wang J
Cell Mol Immunol; 2015 Jan; 12(1):66-76. PubMed ID: 24769795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
